AstraZeneca prices a $2 billion bond issue

AstraZeneca PLC announces that yesterday it conducted a successful global bond market transaction issuing a total of $2 billion of notes. The proceeds of the issue will be used for debt refinancing and general corporate purposes. The transaction, which is an SEC-registered global offering, consists of two tranches:

$1 billion of 7-year fixed rate notes with a coupon of 1.95% and $1 billion of 30-year fixed rate notes with a coupon of 4%.

The notes will be issued under AstraZeneca’s existing automatic shelf registration statement on Form F-3, which AstraZeneca filed with the US Securities and Exchange Commission on 21 December 2010. Such registration statement provides for the offer and sale from time to time of an indeterminate amount of AstraZeneca’s debt securities and includes a prospectus which investors should read to obtain more complete information. The offering was made solely by means of a written prospectus forming part of the registration statement.

A copy of the final prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Goldman Sachs & Co. at +1 866 471 2526, HSBC Securities (USA) Inc at +1 866 811 8049, J.P. Morgan Securities LLC at +1 212 834 4533 or Morgan Stanley & Co. LLC at +1 866 718 1649.